GlaxoSmithKline plc (ADR) (NYSE:GSK)

We always need the stuff they make.

Any kind of breaktrhough in cancer research or possible cure in HIV will make GSK success.

Good year for health care

Good company with a good pipeline of drugs. Strong management team. Strong dividend payment. Good long term bet

Health care industry, 5.28% dividend, low dividend payout percent, history of growing dividend, pharmaceutical with a reasonable pipeline. Depressed earnings due to European crisis and a couple drugs coming off patent protection. Prognosticators are expecting flat earnings for the next two years. With a dividend reinvest position, flat earnings are fine by me. Can yo say cash cow? Share acquisition time people.

Young avg patent life, 12 PE, 4.8% div yield.

over 20 period moving average on a monthly chart

GlaxoSmithKline is better positioned than competitors AstraZeneca and Pfizer. Unlike their competitors the company has already faced its "patent cliff" and is hiring rather than laying off staff. Also, GSK is expecting 30 drugs to reach late-stage development within the next three years.

Another reason to be bullish about GSK is the fact that, among Big Pharma, the company is the leader in antibiotic R&D. I know, I know - antibiotics don't generate the revenue that home-run cancer drugs do. But consider the enormous population affected by infectious disease (much larger than any cancer group) and that an infectious disease drug is twice as likely to be approved than an oncology drug. In fact, infectious disease drugs have the highest success rate in the industry.

Pfizer abandoned its antibiotic R&D in 2011. That leaves GSK and AstraZeneca to duke it out for supremacy. Fortunately for GSK, AZN is busy laying off scientists and lining the pockets of its CEO.

You can laugh today, but antibiotics will be a sizable part of Big Pharma revenue in the next 10 years. No one is better equipped to answer the call than GSK.

World is getting older

simply too cheap

This is a "Giant Tortoise Stock." Like a giant tortoise, It may be big and slow, but it has a hard shell (economic moat), can swim far (enter into new and emerging markets and industries), and live long.

Potential to make somebody some money.

GG Best Buy Now

Access to and strength in emerging markets. A strong dividend is currently underappreciated.

some of the best consumer meds and a good dividend

Aging boomers will swarm on this stock and make sweet, sweet love to it.

div

FDA approval of BENLYSTA will bring profits from US markets and European approval is on the way later this year. Revenues are going to increase immensely over the next few years and unless there is a drug approval that will compete with the current monopolistic standing of this new drug, both Human Genome and Glaxosmithkline will do extremely well.

Excellent management. Solid balance sheet. Strong consumer healthcare, especially in emerging markets. Very strong vaccines division. Doesn't have too many patents expiry issues. Best drugs pipeline of the major pharmaceuticals. Great dividend.